Category Archives: Stem Cell Medical Center


Impact of Covid-19 on Preimplantation Genetic Testing Market is Projected to Grow Massively in Near Future – Cole of Duty

A Global Research Report on the Preimplantation Genetic Testing Market has been published by Reports and Data to provide guidance to the readers already in the industry or people who are planning to enter the market. The report focuses on the current scope as well as on the upcoming growth opportunities in the market for the forecast period. To understand market dynamics, the report also includes reliable data on local consumption and global consumption. The report also mentions details about the leading industry players along with information like the company profiles, product offering and specifications, price, capacity, cost of production, latest technologies, revenue share, contact information, and others.

This is the latest report covering the current COVID-19 scenario. The coronavirus pandemic has greatly affected every aspect of the worldwide industry. It has brought along various changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact are covered in the research report. The report discusses all the major aspects of the market with expert opinions on the current status along with historical data.

Get a Sample PDF Report @ https://www.reportsanddata.com/sample-enquiry-form/2244

The report studies the following companies:

Illumina Inc.; Thermo Fisher Scientific, Inc.; Natera, Inc.; Bioarray S.L.; Good Start Genetics, Inc.; Laboratory Corporation of America Holdings; California Pacific Medical Center; Quest Diagnostics Incorporated; CooperSurgical, Inc.

By Regions:

North America

Europe

Asia-Pacific

Latin America

Middle East & Africa

Get a discount on this report @ https://www.reportsanddata.com/discount-enquiry-form/2244

This research report delivers a 360 overview of the competitive landscape of the Global Preimplantation Genetic Testing Market. Furthermore, it includes massive data regarding the latest trends, technological advancements, and methodologies. The study basically analyzes the Global Preimplantation Genetic Testing Market in a detailed and extensive manner for the readers to gain better insights.

Key questions answered in the report:

Key coverage of the report:

Browse the full report @ https://www.reportsanddata.com/report-detail/preimplantation-genetic-testing-market

The Preimplantation Genetic Testing Market report delivers the principle locale, latest economic situations with the item value, benefits, production capacity, demand and supply, market development rate, and others. Additionally, the report also undertakes SWOT examination, speculation attainability investigation, and venture return investigation.

Thank you for reading our report. For further details or to inquire about customization, please let us know and we will offer you the report as per your needs.

Read more:
Impact of Covid-19 on Preimplantation Genetic Testing Market is Projected to Grow Massively in Near Future - Cole of Duty

Covid-19 Update : Cord Stem Cell Banking Market 2020 Outlook and Deep Study of Top Key Players Cryo-Save AG, Lifecell, StemCyte India Therapeutics…

Global Cord stem cell banking market is estimated to reach USD 13.8 billion by 2026 registering a healthy CAGR of 22.4%. The increasing number of parents storing their childs cord blood, acceptance of stem cell therapeutics, high applicability of stem cells are key driver to the market.

Request for sample copy or PDF Here https://www.databridgemarketresearch.com/request-a-sample?dbmr=global-cord-stem-cell-banking-market

An influential Cord Stem Cell Banking Market report gives an idea about consumers demands, preferences, and their altering likings about particular product. A data triangulation method has been employed in this entire report which entails data mining, analysis of the impact of data variables on the market & primary (industry expert) validation. This market research report has been generated by considering a range of objectives of market research that are vital for the success of Healthcare industry. It evaluates CAGRs in percentages which designate the rise or fall occurring in the market for particular product in the specific forecast period.

Few of the major market competitors currently working in the globalcord stem cell banking marketareCBR Systems, Inc., Cordlife, Cells4Life Group LLP, Cryo-Cell International, Inc., Cryo-Save AG, Lifecell, StemCyte India Therapeutics Pvt. Ltd, Viacord, SMART CELLS PLUS., Cryoviva India, Global Cord Blood Corporation, National Cord Blood Program, Vita 34, ReeLabs Pvt. Ltd., Regrow Biosciences Pvt. Ltd. , ACROBiosystems., Americord Registry LLC., New York Blood Center, Maze Cord Blood, GoodCell., AABB, Stem Cell Cryobank, New England Cryogenic Center, Inc. among others

Browse Detailed TOC, Tables, Figures, Charts and Companies @https://www.databridgemarketresearch.com/toc?dbmr=global-cord-stem-cell-banking-market

Market Definition: Global Cord Stem Cell Banking Market

Cord stem cells banking is nothing but the storing of the cord blood cell contained in the umbilical cord and placenta of a newborn child. This cord blood contains the stem cells which can be used in future to treat disease such as leukemia, thalassemia, autoimmune diseases, and inherited metabolic disorders, and few others.

Segmentation: Global Cord Stem Cell Banking Market

Cord Stem Cell banking Market : By Storage Type

Cord Stem Cell banking Market : By Product Type

Cord Stem Cell banking Market : By Service Type

Cord Stem Cell banking Market : By Indication

Cord Stem Cell banking Market : By Source

Cord Stem Cell banking Market : By Geography

Key Developments in the Cord Stem Cell banking Market:

Cord Stem Cell banking Market : Drivers

Cord Stem Cell banking Market : Restraint

Competitive Analysis: Global Cord Stem Cell Banking Market

Global cord stem cell banking market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions and others to increase their footprints in this market. The report includes market shares of cord stem cell banking market for Global, Europe, North America, Asia Pacific, South America and Middle East & Africa.

Scope of the Cord Stem Cell banking Market Report :

The report shields the development activities in the Cord Stem Cell banking Market which includes the status of marketing channels available, and an analysis of the regional export and import. It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments. This will benefit the reports users, that evaluates their position in Cord Stem Cell banking market as well as create effective strategies in the near future.

Want Full Report? Enquire Here @https://www.databridgemarketresearch.com/inquire-before-buying?dbmr=global-cord-stem-cell-banking-market

About Data Bridge Market Research:

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475 Mail:[emailprotected]

Excerpt from:
Covid-19 Update : Cord Stem Cell Banking Market 2020 Outlook and Deep Study of Top Key Players Cryo-Save AG, Lifecell, StemCyte India Therapeutics...

Coronavirus updates: California to release 8,000 inmates; masks ‘only way’ to prevent another shutdown, Texas Gov. says – USA TODAY

If you thought COVID-19 symptoms couldn't get worse, doctors say a new symptom has emerged. Hallucinations. USA TODAY

A spiking COVID-19 case countis straining Florida's hospital system as nearly half of its intensive care units are at least 90% full, state data shows.

On Thursday, Florida recorded aone-day record of 120 deaths. More than 4,000 people have died there since the start of the pandemic.

Mississippi has also seen a recent strain on its hospitals. Five of the largest medical centers have no ICU bed space for new patients COVID-19 or otherwise and are being forced to turn patients away.

Meanwhile, some states are scaling back reopening guidelines or adding new requirements: Some bars in Nevada will be closing again Friday and restaurants can no longer serve parties more than six people.Kentucky will join the growing list of states that require face coverings in public, too.

In New Mexico, indoor dining at restaurants and breweries will be restricted again starting Monday, and Gov. Michelle Lujan Grisham halted high school sports and said state parks will be closed to out-of-state residents.

Here are some recent developments:

Today's stats:The U.S. has surpassed 3.1 million confirmed cases of COVID-19, the disease caused by the novel coronavirus. More than133,000deaths have been confirmed, according toJohn Hopkins University data. Globally, there have been 12.3 million cases and over 556,000deaths.

What we're reading:ThreeArizona teachers shared a classroom for summer school.They thought they were being "very careful."All threecontracted COVID-19, and one died.The teachers who survived say their colleague's death is a stark reminder of the risks teachers will face if school reopens too soon.

Our live blog will be updated throughout the day. For first-in-the-morning updates,sign upfor The Daily Briefing.

R-0 may be the most important scientific term youve never heard of when it comes to stopping the coronavirus pandemic. USA TODAY

Schools should prioritize safety and rely on local authorities inschool reopening plans, ajoint statementfrom associations of pediatricians, educators and superintendents says.

"Returning to school is important for the healthy development and well-being of children, but we must pursue re-opening in a way that is safe for all students, teachers and staff," the statement says. "Science should drive decision-making on safely reopening schools."

The statement follows a push fromTrump to open schools across the nation andamid a nationwide debate over whether children should return to the classroom.

The statement says the organizations The American Academy of Pediatrics, American Federation of Teachers, the National Education AssociationandThe School Superintendents Association favor a localized approach driven by re experts over a "one-size-fits-all" approach.

In an effort to prevent the spread of COVID-19 in Californiastate prisons, upto 8,000 currently incarcerated people could be released by the end of August, the state's Department of Corrections and Rehabilitation announced Friday.

"Too many people are incarcerated for too long in facilities that spread poor health. Supporting the health and safety of all Californians means releasing people unnecessarily incarcerated and transforming our justice system,"Jay Jordan, Executive Director ofCalifornians for Safety and Justice, said in a press release.

Since the start of the pandemic, the state has releasedabout 10,000 people, according to the state'sDepartment of Corrections.

Activists have repeatedly called on the governor to address the outbreak atSan Quentin prison, where more than 200 staff and more than 1,300 prisoners have active cases, and at least six inmates have died, according to local news reports.

Amid a resurgence of COVID-19 in Georgia, Gov. Brian Kemp announced Friday that the state will reactivate its makeshift coronavirus hospital at a convention center in Atlanta.

The 200-bed temporary hospital at theGeorgia World Congress Centerwas constructed in April but wound down operations at the end of May.

Nearly 3,000 people have died and more than 111,000 people have tested positive for the virus in the state.

At least 47 students at UC Berkeley tested positive for the coronavirus in just one week, and most of the new cases stem from a series of Greek life parties, university officials said.

In a message to the campus community, UniversityHealth Services Medical Director Anna Harte and Assistant Vice Chancellor Guy Nicolette said it was "becoming harder to imagine bringing our campus community back in the way we are envisioning."

"Generally, these infections are directly related to social events where students have not followed basic safety measures such as physical distancing, wearing face coverings, limiting event size, and gathering outside," the officials wrote.

Texas Gov. Greg Abbott begged Texans to mask up in a Friday interview with eastern Texas TV station CBS19, saying face coverings were "the only way"businesses could stay open.

"Its disappointing"that some local officials are refusing to enforce the states mask order, Abbott said. "If we do not all join together and unite in this one cause for a short period of time it will lead to the necessity of having to close Texas back down."

Abbott's ordereffective July 3 requires face masksin public spaces in counties with 20 or more active COVID-19 cases.The order does not apply to people eating,drinking, swimming orexercising or those under 10 years old.

Joel Shannon

West Virginia is among states with the fewest COVID-19 cases, but the state now has the highest coronavirus transmission rate in the country, the head of the state's coronavirus response said Friday.

"The virus is spreading faster person to person in West Virginia right now than in any other state in the country,"Dr. Clay Marsh.The state's "RT value" the average number of people who become infected by an infectious personis the highest in the nation, at 1.37, Marsh said. "We can see that COVID is starting in that logarithmic phase, that compounding phase."

The state has doubled its number of active cases in the last 10-14 days.

Gov. Gretchen Whitmer on Friday expanded Michigan's mask-wearing requirements, effective Monday, saying that wearing masks is the best way to reverse an increase in coronavirus cases.

The order requires the use of face coverings in crowded outdoor spaces and reiterates that individuals are required to wear a face covering whenever they are in an indoor public space. The mandate also requires any business that is open to the public to refuse entry or service to people who refuse to wear a face covering, with limited exceptions.

Paul Egan, Detroit Free Press

Shutting down states in the early days of the US COVID-19 outbreak prevented at least 250,000 deaths and as many as 750,000-840,000 hospitalizations, a new study found. Shelter-in-place orders took about two weeks to show an effect on hospitalizations and three weeks to limit the number of deaths, according to the study by researchers at the University of Iowa and National Bureau of Economic Research.

The authors, who published their results in the journal Health Affairs, also found that deaths from causes other than COVID-19 might have increased if hospitals had become overwhelmed; slowing cases saved those lives, as well, they said.

"These estimates indicate that [stay in place orders] played a key role in flattening the curves not only for cases, but also for deaths and hospitalizations, and eased pressure on hospitals from avoided COVID-19 admissions," the authors conclude.

Karen Weintraub

All 50 states had visitors from Floridathis week, according to data that 15 million U.S. mobile device users provided to the data company Cuebiq. Applying Cuebiqs sample to the whole population, approximately 1.5 million Floridians are now setting up shop in other states.

Residents have left the state in increasing numbers at a time when the crisis there got worse. In early June, just 5% of the states residents appeared in other states. That number has ticked up every week.

Cuebiqs data, which is based on cell phone locations, shows that most interstate visitors from Florida appeared in other parts of the South. About 38% of the states travelers were in Georgia at least once during the week, for example. Alabama, North Carolina, South Carolina and Tennessee also topped the list of destinations for visitors from the hard-struck state.

States outside the region saw big Florida influxes as well. New York, Texas, Pennsylvania and Ohio all had more than 50,000 visits from Florida residents in the most recent week of data, based on an extrapolation of the cell phone location data.

Matt Wynn

New data on the experimental drug remdesivir confirms it can shorten the course of COVID-19 infections and suggests it also can save lives.

Gilead Sciences, Inc., a California pharmaceutical company that makes the drug, revealed data Friday about nearly 400 patients in its late-stage clinical trial.

According to the results, 74% of patients treated with remdesivir had recovered by their 14th day of hospitalization, compared to 59% of those who did not get the drug. Nearly 8% of the patients on remdesivir had died by day 14, versus more than 12% of patients who did not receive it.

The study also found patients who took the drug hydroxychloroquine along with remdesivir fared worse than those on remdesivir alone. The company recommended against using the drugs in combination.

Remdesivir, an antiviral initially developed to treat Ebola, has not yet been approved for widespread use by the U.S. Food and Drug Administration, but it has been given emergency use authorization to treat COVID-19 patients.

Karen Weintraub

Congestion, runny nose, nausea and diarrhea are the four most recent COVID-19 symptoms that the Centers for Disease Control and Prevention added to its growing list of potential signs of the novel coronavirus.

The CDC previously said symptoms include chills, fever, muscle pain, headache, sore throat and a new loss of taste or smell. The agency now lists 11 symptoms on its website.

The additions come as health experts continue to learn more about the disease, and care for very ill COVID-19 patients is improving. Even so, the CDC states the current list doesn't include all possible symptoms for the virus.

Wyatte Grantham-Philips

Fifty-eight Major League Baseball players tested positive for the coronavirus upon reporting to their team, while an additional 13 tested positive after workouts began, according to data released by MLB on Friday.

Perhaps most disconcerting is that 10 teams reported positive test results during what MLB is calling "monitoring testing," meaning one-third of the league's teams had an infected player or staff member after workouts began last week.

Several teams have had workouts halted or curtailed while awaiting test results, and besides those testing positive, players who have come in contact with those testing positive have been temporarily sidelined, as well.

Gabe Lacques

As COVID-19 cases spikeacross, multiple states have taken measures to scale back their reopening plans. Here are some of the last moves:

Read more about states that arepause reopening or take new steps to slow the spread.

A Los Angeles Times report says that researchers are working on an upper-arm injection that would deliverantibody-rich blood plasma of COVID-19 survivors to provide potentially months of protection from the virus.

The approach is similar to one used for other diseases likehepatitis A and could be widely available across the United States, the Times reported.

However, the proposal has received push back from the federal government and pharmaceutical companies, who argue efforts in plasma-based therapy should focus on treating sick people rather than preventing infection, the Times report says.

Dr. Anthony Fauci told the newspaper that the research was promising but more work is needed to show thatcoronavirus antibodies work.

Dr. Anthony Fauci, the nation's top infectious disease expert, said Friday he has not briefed President Donald Trump in at least two months and not seen him in person at the White House since June 2, despite a coronavirus resurgence that has strained hospitals and led several states to pause reopenings.

Fauci told the Financial Times he was "sure" his messages were sent to the president even though the two have not been in close contact in the past several weeks.

The comments from the Trump administration's director of the National Institute of Allergy and Infectious Diseases came as Trump has been critical of Fauci and spoken openly about issues on which they disagree.

In a Thursday interview with Fox News' Sean Hannity, Trump said Fauci had "made a lot of mistakes" but called him a "nice man." Trump also said "most cases" of coronavirus would "automatically cure. They automatically get better."

Fauci also in the FT interview said Trump was incorrect in claiming 99% of coronavirus cases were "harmless" and may have conflated some statistics.

Nicholas Wu

COVID survivors' main symptoms can linger for weeks or even months, causing pain, trouble breathing, nightmares and even organ failure. USA TODAY

Two scientists from the World Health Organization are traveling toBeijing on Friday to lay the groundwork for an investigation into the origins of the new coronavirus.

The researchers,an animal health expert and an epidemiologist, will work with counterparts in China to "look at whether or not it jumped from species to humanand what species it jumped from," WHO spokesperson Dr. Margaret Harris said.

The team will determine the logistics, locations and participantsfor a WHO-led international mission.

The virus was first detected in the central Chinese city of Wuhan late last year. Scientists believe the novel virusoriginated in bats, transferred to another mammal then jumpedto humans.

The Trump administration this week officially began withdrawing the United Statesfrom the WHO, of which President Donald Trump and his advisers have been sharply critical.

Americans are three times as likely to know someone in their community who has been sick with the coronavirus than they did in March, according to a new survey.

More than one-third of Americans (36%) say someone they know outside of their immediate family or work has been sick with the coronavirus, according to a new survey from the Democracy Fund + UCLA Nationscape Project. That number is more than triple the number in mid-March, when it was 11%.

The survey also showed Black (11%) and Latino (11%) Americans are more likely than white Americans (7%) to have had an immediate family member get sick, according to the survey. These racial differences were not apparent in the survey from March.

Rebecca Morin

Nearly half of Florida's intensive-care units are at least 90% full, and more than 1 in 5 are completely full, according to state data.

Hospitals are increasingly strained under COVID-19, andhospitalizations across the state have jumped more than 13% just since July 1. More than 17,100 Floridians have been hospitalized for COVID-19 since the start of the pandemic.

A total of 95 hospital ICUs were at least 90% full Thursday, according to the Florida Agency for Health Care Administration. That's nearly half the 207 ICUs that the agency is tracking. At least 45 hospital ICUs were at capacity, and 46 others had only one bed available in the units.

At least 4,111 people in Florida have died from the virus, according to the state a figure that would have made it the ninth leading cause of death in Florida last year, according to Florida Department of Health statistics. Florida set a one-day record Thursday with 120 deaths. The previous high, 83, was in late April.

Frank Gluck, Fort Myers News-Press

The five largest medical centers in Mississippi have no ICU bed space for new patients coronavirus or otherwise and are being forced to turn patients away, even as COVID-19 continue to surge.

In some cases, patients are being sent to facilities out of state and as far away as New Orleans. In many hospitals, patients admitted to the ER are being forced to spend the night before they receive treatment.

"(Wednesday), five of our biggest hospitals in the state had zero ICU beds. Zero," State Health Officer Dr. Thomas Dobbs said. "Our biggest medical institutions who take care of our sickest patients have no room."

The transition from shelter-in-place to where we currently stand, with the highest number of hospitalizations since the first reported case of the coronavirus virus on March 11, has left the state "wide open," said Dr. Louann Woodward, UMMC vice chancellor for health affairs.

Justin Vicory, Mississippi Clarion Ledger

California is set to become the first state to file a lawsuit against the Trump administration over anew policy that prevents international students from staying in the U.S. if their college or university switches to online-only classes in the fall because of the coronavirus pandemic.

The announcement comes a day after some colleges and universities filed similar lawsuits or announced plans to do so.

The Trump administration revealed its new guidelines in a memo issued by Immigration and Customs Enforcement on Monday. It says that international students will have to leave the country, or face possible deportation, if their schools switch to remote learning, which many have planned to do amid the pandemic.

President Donald Trumps attack on his own health experts guidance for safely reopening schools cracked open for public display a power strugglewithin the administration that has been building for months.

Trump blasted the guidance issued by the Centers for Disease Control and Prevention on Wednesday as very tough & expensive and asking schools to do very impractical things.

But CDC Director Dr. Robert Redfield said on Thursday the guidance would stand, and his staff would provide some new documents to clarify the recommendations.

Theflare-up punctuates a conflict escalating for months, with the nations top scientists publicly sidelined in the Trump administrations initial coronavirus response. Earlier disagreements delayed the release of the reopening guidance for schools and businesses.

Public health leaders who worked at the CDC under prior presidents said they had never seen anything like this weeks open discord."It underminesleadership for everyone involved, said Dr.JeffreyKoplan, a former CDC director."It's public health malpractice to say, 'Open without worrying about anything.'"

Brett Murphy and Letitia Stein

What's actually in the CDC school guidelines?These are the highlights.

Read more:
Coronavirus updates: California to release 8,000 inmates; masks 'only way' to prevent another shutdown, Texas Gov. says - USA TODAY

BCLI: KOL Event Gives Overview of the use of NurOwn in Alzheimer’s Disease; Raising Valuation to $25/Share – Zacks Small Cap Research

By David Bautz, PhD

NASDAQ:BCLI

READ THE FULL BCLI RESEARCH REPORT

Business Update

KOL Event for Alzheimers Program

On July 8, 2020, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) conducted a Key Opinion Leader (KOL) webinar to discuss the companys upcoming Phase 2a clinical trial of NurOwn in patients with Alzheimers Disease (AD). The event included presentations by two of the lead investigators for the upcoming trial, Dr. Philip Scheltens, Professor of Cognitive Neurology and Director of the Alzheimer Centre at VU University Medical Center in Amsterdam, Netherlands, and Dr. Bruno Dubois, Professor of Neurology at the Neurological Institute of the Salptrire University Hospital in Paris, France. The presentation can be found here.

The companys Phase 2a trial (BCT-201-EU) is expected to enroll approximately 40 patients with prodromal to mild AD. It will be taking place at medical centers in France and the Netherlands. To be eligible for the trial, patients must have been diagnosed with prodromal to mild dementia at least six months prior to enrollment. In addition, patients must score between 20-30 on the Mini-Mental State Exam (MMSE) and have a Clinical Dementia Rating (CDR) global score of 0.5-1.0. The MMSE is a series of questions that are designed to assess a patients mental skills, with the maximum score being 30 points and a score of 20-24 suggesting mild dementia. The CDR is a scale used to characterize six domains of cognitive and functional performance with a score of 0.5 suggesting very mild dementia and a score of 1.0 suggesting mild dementia.

The primary objective of the trial is to assess the safety and tolerability of three intrathecal injections of NurOwn in AD patients. Following bone marrow aspiration during a 10-week run-in period, patients will be treated three times with NurOwn, with eight weeks between treatments. Follow-up visits will occur 12 and 26 weeks following the final injection of NurOwn for a total trial length of 52 weeks. The following figure gives an overview of the trial design.

Cerebrospinal fluid (CSF) and serum will be collected prior to treatment and again at Weeks 0, 8, and 16 to assess changes in various neurotropic, neurodegenerative, and inflammatory factors (e.g., VEGF, HGF, NfL, NfH, MCP-1, IL-6), markers associated with amyloid deposition (e.g., a40, a42), and markers of tau protein levels (e.g., p-tau, t-tau). Additional clinical outcome measures will be analyzed through administration of the following tests:

Clinical Dementia Rating ScaledSum of Boxes (CDR-SB)

Free and Cued Selective Reminding Test (FCSRT)

Neuropsychological Test Battery (NTB)

Delis-Kaplan Executive Function System (D-KEFS) subtests

Mini Mental State Examination(MMSE)

AmsterdamInstrumentalActivitiesofDailyLivingQuestionnaire-ShortVersion(A-IADL-Q-SV)

Alzheimers Disease

Alzheimers disease (AD) is the most common form of dementia in older adults. The disease is named after Dr. Alois Alzheimer, who identified the first case in a 50-year-old woman named Auguste Deter in 1902. Dr. Alzheimer followed her case until her death in 1906, at which point he first publicly reported on it (Alzheimer, 1907).

After Ms. Deters death, Dr. Alzheimer examined her brain and found many abnormal clumps (now known as amyloid plaques) and tangled bundles of fibers (now known as neurofibrillary tangles). Over the next five years, 11 similar cases were reported in the medical literature, with some of them already using the term Alzheimers disease (Berchtold et al., 1998).

The most common early symptom of AD is a gradually worsening ability to remember new information. This is due to neurons associated with forming new memories dying off first. As neurons in other parts of the brain die, individuals experience different symptoms, which include:

Memory loss that disrupts daily life

Inability to plan or solve problems

Difficulty completing familiar tasks

Confusion with location and time

Difficulty with visual images and spatial relationships

Problems with words in speaking or writing

Withdrawal from social activities

Changes in mood, including apathy and depression

Each person progresses through AD at a different rate, and little is known about how or why there is such a marked variation, thus predicting how it will affect someone is quite difficult. One thing that is common to everyone diagnosed with AD is that his or her cognitive and functional abilities will gradually decline. As the disease progresses symptoms can include confusion, irritability, aggression, mood swings, and long-term memory loss. In the final advanced stage of the disease, people need help with the basic activities of living (e.g., bathing, dressing, eating, and using the restroom), they lose the ability to communicate, fail to recognize loved ones, and eventually become bed bound and reliant on round-the-clock care (Frstl et al., 1999). The inability to move makes them more prone to infections, including pneumonia, which are often a contributing factor to the death of those with AD.

Competing Theories for the Cause of Alzheimers

The root cause of Alzheimers is still unknown; however, it is likely to involve a number of different factors as opposed to being due to one single cause. These factors are likely a combination of genetic, environmental, and lifestyle. There are a number of hypotheses that exist to explain the cause of the disease, with the two dominant hypotheses focused on amyloid and tau.

Amyloid hypothesis: This hypothesis proposes that extracellular beta-amyloid deposits are the fundamental cause of the disease (Hardy et al., 1991). Beta-amyloid is a fragment of the larger protein amyloid precursor protein (APP), mutations of which are known to cause FAD. Several lines of evidence support the amyloid hypothesis: 1) the location of APP is on chromosome 21, while those with Down Syndrome (trisomy 21) almost all show signs of AD by 40 years of age (Lott et al., 2005); 2) APOE4 is a major genetic risk factor for AD, and while apolipoproteins enhance the breakdown of beta-amyloid, some isoforms are less capable of performing this task than others, leading to more beta-amyloid buildup on the brain (Polvikoski et al., 1995); 3) mice that harbor a mutant form of APP develop amyloid plaques and Alzheimers-like pathology (Games et al., 1995). Lastly, amyloid plaques are readily identifiable by microscopy in the brains of AD patients (Tiraboschi et al., 2004). While the brains of many older individuals develop some plaques, the brains of AD patients show severe pathological changes specifically within the temporal neocortex (Bouras et al., 1994).

Tau hypothesis: Tau is a protein located mainly within the axonal compartment of neurons and is an important element in microtubule stabilization and neurite outgrowth. In AD, a proportion of tau protein becomes abnormally phosphorylated, dissociates from axonal microtubules, and accumulates in paired helical filaments inside the neuron (Goedert et al., 1991). When this occurs, the microtubules disintegrate causing the collapse of the neurons transport system (Igbal et al., 2005). Just as with beta-amyloid plaques, tau tangles are readily observable in the brains of those affected by AD.

In addition to amyloid and tau, inflammation has been an underappreciated and often overlooked mediator in patients with AD (Akiyama et al., 2000). A multitude of inflammatory markers are found in AD patients brains and a number of studies have shown a link between chronic inflammation and an increased risk of developing AD (Walker et al., 2017; Tao et al., 2018). Thus, a treatment such as NurOwn that can decrease inflammatory mediators could prove beneficial in AD patients.

On Track to Repot Topline Data from Phase 3 ALS Trial in 4Q20

On July 2, 2020, BrainStorm announced that all doses have been administered in the pivotal Phase 3 trial ofrecen NurOwn in patients with amyotrophic lateral sclerosis (ALS) and that it remains on track to report topline data in the fourth quarter of 2020.

The ongoing randomized, double blind, placebo controlled, multi-dose Phase 3 clinical trial is testing the ability of NurOwn to alter disease progression as measured by the ALSFRS-R (NCT03280056). Cells were extracted once from each patient prior to treatment, with all administrations of NurOwn derived from the same extraction of cells due to a cryopreservation process the company developed for long-term storage of mesenchymal stem cells (MSC). Just as with the companys prior studies, there was a 3-month run-in period prior to the first treatment with two additional NurOwn treatments occurring two and four months following the first treatment. The company is focusing the trial on faster-progressing ALS patients since those patients demonstrated superior outcomes in the Phase 2 trial of NurOwn.

BrainStorm Joins Russell 2000 and Russell 3000; Granted SME Status by EMA

On June 23, 2020, BrainStorm announced that its shares would be included in the Russell 2000 Index and the Russell 3000 Index. The annual reconstitution of the Russell indexes is done to capture the 4,000 largest U.S. stocks by market capitalization.

On June 15, 2020, BrainStorm announced that the company has been granted Small and Medium-Sized Enterprise (SME) status by the European Medicines Agency (EMA). SME status allows the company to participate in a number of financial incentives including a 90-100% reduction in the EMA fee for scientific advice, clinical study protocol design, endpoints and statistical considerations, quality inspections of facilities, and fee waivers for selective EMA pre- and post-authorization regulatory filings, including Orphan Drug and PRIME designations.

Conclusion

Were excited about the potential for NurOwn in AD and we look forward to the initiation of the Phase 2a trial later in 2020. We have recently made a few changes to our model, including the inclusion of NurOwn in AD and lowering of the discount rate from 20% to 15% for all indications. We model for the company to file for approval of NurOwn in AD in 2026 and to be granted approval in 2027. We currently estimate peak sales of over $2 billion for NurOwn in AD in both the U.S. and E.U. Using a 25% probability of approval leads to an NPV of $113 million. Combined with the NPV for NurOwn in ALS ($700 million) and MS ($41 million) along with the companys current cash position and potential cash from warrants leads to a valuation for the company of a bit less than $900 million. Dividing by the companys current fully diluted share count of 35.7 million leads to a valuation of $25 per share.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCHtoreceive our articles and reports emailed directly to you each morning. Please visit ourwebsitefor additional information on Zacks SCR.

DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $40,000 annually for these services. Full Disclaimer HERE.

Link:
BCLI: KOL Event Gives Overview of the use of NurOwn in Alzheimer's Disease; Raising Valuation to $25/Share - Zacks Small Cap Research

Hammond police officer jumps at chance to donate stem cells – The Times of Northwest Indiana

The grandmother of a local boy fighting cancer explained a swab would be taken from their mouths and sent off for analysis. If they were determined to be a match for someone in need, they would be notified.

Its hard to get a match, Seles said. But if you do, they ask, 'Would you be interested in following through?'"

Seles and his wife both signed up, but so far Courtney Seles hasnt received a call.

Adam learned in summer 2019 that he was a match and the recipient would need a donation within just four to six weeks.

He traveled with his father, Nathan Seles, 58, to Grand Rapids for a physical and blood draw. While they were at the facility, staff worked to ensure Seles was comfortable and wanted to follow through with the donation process.

At one point, he looked over and saw his father was crying, he said.

It means a lot to him, Seles said of his dad. Hes dealt with cancer a few times. It means a lot to him that I can do something.

Seles began the injections at home with the help of his mother-in-law, a nurse, he said.

Medical staff warned he could feel pain in the back or legs, because the medication being injected allows stem cells to pass from the bone marrow into the blood stream.

Visit link:
Hammond police officer jumps at chance to donate stem cells - The Times of Northwest Indiana

Joint Study by Sunway University and Harvard Medical School Shows Gene Therapy Can Advance Cancer Treatment – QS WOW News

Sunway Universitys Professor Jeff Tan Kuan Onn of the Department of Biological Sciences and Professor Poh Chit Laa from the Centre for Virus and Vaccine Research, along with their research collaborators from Harvard Medical Schools Center for Stem Cell Therapeutics and Imaging (USA) as well as University of Tennessee Health Science Centre (USA) have completed a study that has demonstrated the efficacy of molecular gene therapy as a new strategy for cancer treatment.

The research could potentially contribute to shorter treatment time for cancers, reduce treatment costs and minimize the adverse effects of current chemo-drugs in cancer patients such as susceptibilities toward microbial infections, hair loss, and other side effects of chemo-drugs that drastically affect the quality of life of cancer patients undergoing therapy.

Principal Investigator Professor Jeff Tan explained, Currently, chemo-drugs are relatively ineffective against cancer cells that have developed drug-resistance resulting in the need for high doses of chemo-drugs or a combination of chemo-drugs to be administered to patients with cancer cells. Chemo-drug resistant cancer cells also can spread quickly and that drastically reduce the survival rate of cancer patients.

Our research utilizes molecular gene therapy which is the introduction of genetic materials into cancer cells to promote the sensitivity of cancer cells to chemo-drugs. By genetically engineering the cancer cells, we find that we can induce the cancer cells to produce activated pro-death and tumor suppressor proteins that cause cell death and growth arrests in cancer cells. The weakened cancer cells can then be killed relatively easily by the administration of chemo-drugs in smaller doses. Ultimately, the research could contribute to increasing the survival rates of cancer patients undergoing cancer treatments he added.

Co-Investigator Professor Poh Chit Laa said that the effectiveness of the strategy has been demonstrated in mice implanted with human breast cancer cells. In the mice that were treated with the gene therapy, the tumors obtained from the treated mice showed significant tumor cell death and the tumors were 20 times smaller and 32 times lighter in volume and weight, respectively, when compared to the tumors obtained from the untreated mice. The results indicated that gene therapy was able to shrink the tumors significantly, even without treatment with chemo-drugs. Small doses of market-available anti-cancer drugs could then be used to kill the cancer cells effectively. We hope to see our research contribute to better survival rates of cancer patients, and minimize the side-effects associated with anti-cancer drugs, said Professor Poh.

We are currently working on investigations to optimize the delivery of the gene therapy and anti-cancer drugs to human tumors with hopes that this will result in tangible clinical outcomes, said Professor Jeff Tan.

The research project was recently published in the peer-review Journal of Cancer Research and Clinical Oncology. Collaborators for the research include Lee Yong Hoi, Pang Siew Wai and Samson Eugin Simon from the Department of Biological Sciences, Sunway University; Esther Revai Lechtich and Khalid Shah, of the Center for Stem Cell Therapeutics and Imaging, Brigham and Womens Hospital, Harvard Medical School (USA); Suriyan Ponnusamy and Ramesh Narayanan from the Department of Medicine, Centre of Cancer Drug Discovery, College of Medicine, University of Tennessee Health Science Centre (USA).

The research is a result of a collaboration agreement between Harvard Medical School and Sunway University aimed at developing new cancer therapies targeting drug-resistant cancer cells. In 2016, Professor Jeff Tan visited Harvard University on the Jeffrey Cheah Travel Grant which enabled him to better understand how cancer research projects are conducted as well as examining experimental models used to study cancer biology at Harvard University, Massachusetts General Hospital (MGH), a hospital affiliated with Harvard Medical School, and the Dana-Farber Cancer Institute.

To read the jointly published article: https://link.springer.com/article/10.1007/s00432-020-03231-9

See more here:
Joint Study by Sunway University and Harvard Medical School Shows Gene Therapy Can Advance Cancer Treatment - QS WOW News

Astex Pharmaceuticals, Taiho Oncology, and Otsuka Pharmaceutical Announce FDA and Health Canada Approval of INQOVI (Decitabine and Cedazuridine)…

INQOVI is the first and only orally administered hypomethylating agent for the treatment for adults with intermediate and high-risk myelodysplastic syndromes (MDS) including chronic myelomonocytic leukemia (CMML),1 two blood malignancies.

Approval was based on data from the ASCERTAIN phase 3 study and supporting phase 1 and 2 clinical studies. The ASCERTAIN phase 3 study evaluated the five-day, decitabine exposure equivalence between oral INQOVI and intravenous decitabine. The safety and efficacy of INQOVI was also assessed in the clinical studies.

The review and approval of INQOVI was conducted under the ORBIS initiative from the FDA Oncology Center of Excellence (OCE) with simultaneous submission and regulatory review in the U.S., Canada, and Australia. The FDA also reviewed the NDA under Priority Review status. INQOVI is not currently approved in Australia. INQOVI was formerly named ASTX727, its experimental compound code.

Intravenous or subcutaneous administered hypomethylating agents have been the cornerstone for the treatment of patients with MDS and CMML since the mid-2000s, said Guillermo Garcia-Manero, MD, Professor and Chief of Section of Myelodysplastic Syndromes, Department of Leukemia at The University of Texas MD Anderson Cancer Center, Houston, Texas, and Principal Investigator of the ASCERTAIN clinical study. The FDAs approval of INQOVI builds on the proven therapeutic utility of hypomethylating agents in these diseases and offers a new orally administered option that offers patients an alternative to five consecutive days of IV infusions every month during a treatment period that can extend to several months.

Until now, patients with intermediate and high-risk MDS and CMML have not had an approved, orally administered hypomethylating agent option for treatment of their disease, said Mohammad Azab, MD, president and chief medical officer of Astex Pharmaceuticals, Inc. The INQOVI clinical program was designed to deliver an oral alternative to IV decitabine based on comparative decitabine exposure data in the clinical trials, and to assess INQOVIs safety and efficacy profile. As part of the ORBIS project initiative of FDA and Health Canada we were able to share and address information requests simultaneously with both agencies resulting in a more efficient review and completion of assessment in a timely manner. The outcome is expedited availability of this important oral alternative to patients in both countries, added Dr. Azab. We greatly appreciate the FDAs priority review and Health Canadas review of the INQOVI NDA / NDS under Project ORBIS and the approval of a new therapeutic option for patients with these diseases.

INQOVI is an orally administered, fixed-dose combination of the approved anti-cancer DNA hypomethylating agent, decitabine, together with cedazuridine,2 an inhibitor of cytidine deaminase.3 By inhibiting cytidine deaminase in the gut and the liver, INQOVI is designed to allow for oral delivery of decitabine over five days in a given cycle to achieve comparable systemic exposure to IV decitabine (geometric mean ratio of the 5-day cumulative decitabine area-under-the-curve following 5 consecutive once daily doses of INQOVI compared to that of intravenous decitabine was 99% (90% CI: 93, 106).1 The phase 1 and phase 2 clinical study results have been published in Lancet Haematology4 and Blood,5 respectively. The phase 3 ASCERTAIN study data was presented at the American Society of Hematology (ASH) Meeting in Orlando, Florida, in December 2019 by Dr. Garcia-Manero.6

Astexs parent company, Otsuka Pharmaceutical Co., Ltd., and Taiho Pharmaceutical Co., Ltd. previously announced that, subject to regulatory approvals, commercialization of oral INQOVI in the U.S. and Canada will be conducted by Taiho Oncology, Inc. and Taiho Pharma Canada, Inc. respectively.

Our partnership with Astex is a demonstration of the commitment that Taiho Oncology has to bringing new therapeutic options to patients with cancer, said Tim Whitten, president and chief executive officer of Taiho Oncology, Inc. The approval of INQOVI makes the possibility of at-home hypomethylating agent treatment of intermediate and high-risk MDS and CMML a reality, enabling patients to take their medication from the convenience and comfort of their home. This is especially significant during the COVID-19 pandemic, allowing patients to potentially reduce the number of office visits needed for current IV treatment administration. We look forward to working with all healthcare professionals to help deliver the first new oral HMA treatment alternative for patients with intermediate and high-risk MDS and CMML in nearly fifteen years.

About INQOVI (See https://www.inqovi.com)

INQOVI is indicated for treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.1

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Myelosuppression: Fatal and serious myelosuppression can occur with INQOVI. Based on laboratory values, new or worsening thrombocytopenia occurred in 82% of patients, with Grade 3 or 4 occurring in 76%. Neutropenia occurred in 73% of patients, with Grade 3 or 4 occurring in 71%. Anemia occurred in 71% of patients, with Grade 3 or 4 occurring in 55%. Febrile neutropenia occurred in 33% of patients, with Grade 3 or 4 occurring in 32%.

Fatal and serious infectious complications can occur with INQOVI. Pneumonia occurred in 21% of patients, with Grade 3 or 4 occurring in 15%. Sepsis occurred in 14% of patients, with Grade 3 or 4 occurring in 11%. Fatal pneumonia occurred in 1% of patients, fatal sepsis in 1%, and fatal septic shock in 1%.

Obtain complete blood cell counts prior to initiation of INQOVI, prior to each cycle, and as clinically indicated to monitor response and toxicity. Administer growth factors, and antiinfective therapies for treatment or prophylaxis as appropriate. Delay the next cycle and resume at the same or reduced dose as recommended.

Embryo-Fetal Toxicity: INQOVI can cause fetal harm. Advise pregnant women of the potential risk to a fetus. Advise patients to use effective contraception during treatment with INQOVI and for 6 months (females) or 3 months (males) after last dose.

ADVERSE REACTIONS

Serious adverse reactions in > 5% of patients included febrile neutropenia (30%), pneumonia (14%), and sepsis (13%). Fatal adverse reactions included sepsis (1%), septic shock (1%), pneumonia (1%), respiratory failure (1%), and one case each of cerebral hemorrhage and sudden death.

The most common adverse reactions ( 20%) were fatigue, constipation, hemorrhage, myalgia, mucositis, arthralgia, nausea, dyspnea, diarrhea, rash, dizziness, febrile neutropenia, edema, headache, cough, decreased appetite, upper respiratory tract infection, pneumonia, and transaminase increased. The most common Grade 3 or 4 laboratory abnormalities (>50%) were leukocytes decreased, platelet count decreased, neutrophil count decreased, and hemoglobin decreased.

USE IN SPECIFIC POPULATIONS

Lactation: Because of the potential for serious adverse reactions in the breastfed child, advise women not to breastfeed during treatment with INQOVI and for at least 2 weeks after the last dose.

Renal Impairment: No dosage modification of INQOVI is recommended for patients with mild or moderate renal impairment (creatinine clearance [CLcr] of 30 to 89 mL/min based on Cockcroft-Gault). Due to the potential for increased adverse reactions, monitor patients with moderate renal impairment (CLcr 30 to 59 mL/min) frequently for adverse reactions. INQOVI has not been studied in patients with severe renal impairment (CLcr 15 to 29 mL/min) or end-stage renal disease (ESRD: CLcr <15 mL/min).

Please see the accompanying Full Prescribing Information.

https://www.inqovi.com/pi

To view the FDA Press Release, please see the following link.

https://www.fda.gov/news-events/press-announcements/fda-approves-new-therapy-myelodysplastic-syndromes-mds-can-be-taken-home

About Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Myelodysplastic syndromes are a heterogeneous group of hematopoietic stem cell disorders characterized by dysplastic changes in myeloid, erythroid, and megakaryocytic progenitor cells, and associated with cytopenias affecting one or more of the three lineages. U.S. incidence of MDS is estimated to be 10,000 cases per year, although the condition is thought to be under-diagnosed.7,8 The prevalence has been estimated to be from 60,000 to 170,000 in the U.S.9 MDS may evolve into acute myeloid leukemia (AML) in one-third of patients.10 The prognosis for MDS patients is poor; patients die from complications associated with cytopenias (infections and bleeding) or from transformation to AML.

CMML is a clonal hematopoietic malignancy characterized by accumulation of abnormal monocytes in the bone marrow and in blood. The incidence of CMML in the U.S. is approximately 1,100 new cases per year,11 and CMML may transform into AML in 15% to 30% of patients.12 The hypomethylating agents decitabine and azacitidine are effective treatment modalities and are FDA-approved for the treatment of intermediate and high-risk MDS and CMML. These agents are administered by IV infusion, or by large-volume subcutaneous injections.

About Astex, Taiho, and Otsuka

Astex is a leader in innovative drug discovery and development, committed to the fight against cancer. Astex is developing a proprietary pipeline of novel therapies and has multiple partnered products in development under collaborations with leading pharmaceutical companies. Astex is a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., based in Tokyo, Japan.

Taiho Oncology, Inc., is a subsidiary of Taiho Pharmaceutical Co., Ltd. and an indirect subsidiary of Otsuka Holdings Co., Ltd. Taiho has established a world-class clinical development organization that works urgently to develop innovative cancer treatments and has built a commercial business in the U.S. Taiho has an oral oncology pipeline consisting of both novel antimetabolic agents and selectively targeted agents.

Otsuka Pharmaceutical is a global healthcare company with the corporate philosophy: Otsukapeople creating new products for better health worldwide. Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and nutraceutical products for the maintenance of everyday health.

For more information about Astex Pharmaceuticals, Inc. please visit: https://www.astx.com

For more information about Otsuka Pharmaceutical, please visit: https://www.otsuka.co.jp/en/

For more information about Taiho Pharmaceutical, please visit: https://www.taihooncology.com/

References

CDEC-PM-US-0125

View source version on businesswire.com: https://www.businesswire.com/news/home/20200707005938/en/

More here:
Astex Pharmaceuticals, Taiho Oncology, and Otsuka Pharmaceutical Announce FDA and Health Canada Approval of INQOVI (Decitabine and Cedazuridine)...

HRMC to open hematology and oncology clinic – The Ottawa Herald

On Aug. 4, Hutchinson Regional Medical Center will open the Hutchinson Hematology and Oncology clinic. Dr. Sawsan Amireh will join the Hutch Regional team that day and see her first patients at her clinic which will be located in Suite 4 of Doctors Park at 2100 N. Waldron St., a building located to the southwest of the main hospital campus on the east side of Waldron Street.

Hematology and Oncology are two branches of medicine that continue to be a concern of members of our community and throughout the State of Kansas.

Oncology is the branch of medical science dealing with tumors, including the diagnosis and treatment of cancer. More than 1.8 million Americans, including 16,000 Kansans, are diagnosed with cancer each year. For more than 600,000 of our nations population each year, cancer is a terminal disease. The good news is that 17 million Americans are living out their lives as cancer survivors.

Cancer is best defined as the uncontrolled growth and spread of abnormal cells and the cause is often attributed to everything from heredity to an unhealthy lifestyle including tobacco use and excess weight. Treatments are medical, surgical, Chemotherapy and Radiation.

Hematology is the branch of medicine dealing with the cause, treatment and prevention of disease related to the blood. Specific issues dealt with include treatment of bleeding disorders, Lymphoma and Leukemia and blood transfusions, along with bone marrow and stem cell transplants.

Dr. Amireh, who has received training on the latest treatment protocols, arrives at Hutch Regional with impeccable credentials and is Board Certified in Internal Medicine. She received her doctorate degree in 2011 from the University of Jordan School of Medicine in Amman, Jordan. Since 2017, Dr. Amireh has participated in a Hematology and Oncology Fellowship and also served as chief fellow with the State University of New York Downstate Health Science Center in Brooklyn, New York. Also, Dr. Amireh served as Associate Chief Medical Resident and Internal Medical Resident at Saint Michaels Medical Center in New Jersey.

In 2010, Dr. Amireh completed special training at Vanderbilt University Medical Center in Nashville, Tennessee on Hepatology and Pediatric Endocrinology. She has won numerous awards and honors including the Clinical Documentation Excellence Award from St. Michaels Medical Center, the Academic Excellence Award from the University of Jordan School of Medicine, and the English Talented Writing Award from the University of Jordan.

Dr. Amireh is a member of the American Society of Clinical Oncology, American Society of Hematology, American College of Physicians, and the Jordan Medical Association.

Dr. Amireh said Oncology has entered a new era with the onset of COVID-19. "Cancer patients are now more vulnerable and will need to be more diligent to avoid infection which proves that life is more fragile than it once was," Dr. Amireh said. "I am looking forward to starting a hospital-based practice. We have a young family and southcentral Kansas is a good place to raise a two-year old. New York is too busy and not really family friendly."

"I want my practice to be inclusive and will welcome everyone who needs treatment and care," Dr. Amireh continued.

Appointments with Dr. Amireh will be accepted starting in Mid-July. Additional information including her clinics contact information will be published at that time.

With the opening of Hutchinson Hematology and Oncology, south central and western Kansas will have a new choice for quality cancer care. Dr. Amireh will provide a caring, personal approach to cancer care and her clinic will work in tandem with the Chalmers Cancer Center and the other Hutchinson Regional Healthcare System entities as well as other physician specialties in Hutchinson and surrounding communities to provide an integrated approach to care in Hutchinson.

Dr. Amireh will join her spouse, Dr. Mohammed "Mo" Al-Halawani at Hutch Regional. In July 2019, Dr. Al-Halawani joined Dr. Tariq Musa in opening Hutchinson Pulmonology Associates at Hutchinson Regional Medical Center. Dr. Al-Halawani and Dr. Musa hit the ground running and are serving patients in Hutchinson as well as an outreach clinic in McPherson, with plans to support pulmonary needs locally and in the surrounding areas.

We are excited that these high caliber healthcare professionals have chosen to move across America to provide their expertise to residents on the plains of Kansas.

Ken Johnson is the President and CEO of Hutchinson Regional Medical Center.

See the original post here:
HRMC to open hematology and oncology clinic - The Ottawa Herald

Gift of Life, Root and Rutgers Researchers Launch COVID-19 Study – Patch.com

This post was contributed by a community member. The views expressed here are the author's own.

Boca Raton, FL, June 29 Human leukocyte antigens (HLA) diverse genetic markers on our cells that help match patients and donors for bone marrow transplant are the focus of a new study led by the Gift of Life Marrow Registry.

The study, in collaboration with researchers at Rutgers Cancer Institute of New Jersey and the genetic crowd science portal Root, aims to help answer a key question: why do some people get COVID19 or particular symptoms, while others avoid them? More than 350,000 donors in Gift of Life's registry have been invited to participate, helping researchers answer this important question.

"Every volunteer donor is already HLA-typed, presenting a tremendous opportunity to drive broader science through the prism of these immune-related genes," said Gift of Life's Founder and CEO Jay Feinberg. "We're excited to help the world understand how our immune systems may shape the pandemic."

"We hope to learn whether immune-vital tissue match genes such as HLA help explain why some of us avoid COVID-19, while others get severe symptoms or need particular treatments," said the study's principal investigator Jeffrey Rosenfeld, PhD, Assistant Professor of Pathology and Laboratory Medicine, Rutgers Robert Wood Johnson Medical School. "Adding such key data to the fight against COVID-19, we can help solve the mystery of why it affects different people so differently."

Subscribe

Root's founder, geneticist Nathaniel Pearson, PhD, noted that "because transplant registries read HLA genes better than consumer DNA tests do, a study like this can best reveal how these diverse, immune-vital genes may shape COVID-19. Gift of Life members, who have long saved lives via transplants, now show us how everyday people can help the world beat a pandemic too."

Participants can also opt into short monthly surveys for the coming year, even if they have never had COVID-19. The researchers will study their de-identified data, to better understand how tissue match genes and other factors may figure in COVID-19 risks and outcomes.

Subscribe

The new study furthers Gift of Life's efforts to help people and communities in need during the pandemic. The organization has increased capacity at the Dr. Miriam and Sheldon G. Adelson Gift of LifeBe The Match Collection Center to become a non-hospital based go-to for stem cell donations and contributed 10,000 specialized swabs to Baptist Health South Florida via Boca Raton Regional Hospital to be used for COVID-19 testing.

About Gift of Life Marrow Registry The Gift of Life Marrow Registry is a 501(c)(3) nonprofit organization headquartered in Boca Raton, Fla. The organization, established in 1991, is dedicated to saving lives by facilitating bone marrow and blood stem cell transplants for patients with leukemia, lymphoma, and other blood-related diseases. To learn more about Gift of Life or to make a tax-deductible donation, visit http://www.giftoflife.org.

About Rutgers Cancer Institute of New Jersey As New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute, along with its partner RWJBarnabas Health, offers the most advanced cancer treatment options including bone marrow transplantation, proton therapy, CAR T-cell therapy and complex robotic surgery. Along with clinical trials and novel therapeutics such as precision medicine and immunotherapy many of which are not widely available patients have access to these cutting-edge therapies at Rutgers Cancer Institute of New Jersey in New Brunswick, Rutgers Cancer Institute of New Jersey at University Hospital in Newark, as well as through RWJBarnabas Health facilities.

Along with world-class treatment, which is often fueled by on-site research conducted in Rutgers Cancer Institute laboratories, patients and their families also can seek cancer preventative services and education resources throughout the Rutgers Cancer Institute and RWJBarnabas Health footprint statewide. To make a tax-deductible gift to support the Cancer Institute of New Jersey, call 848-932-8013 or visit http://www.cinj.org/giving.

About Root

Root (rootdeep.com) works to grow, diversify, and engage the ranks of blood and marrow volunteers earth's biggest group of living, contactable DNA data owners to save patients in need, honor their good will with good insights, and empower them to spark broader health science discoveries with researchers.

The views expressed in this post are the author's own. Want to post on Patch? Register for a user account.

Patch is a space for neighborhood news. Please keep your replies clean, friendly and factual. Read our community guidelines here

Reply to this articleReply

Read the original post:
Gift of Life, Root and Rutgers Researchers Launch COVID-19 Study - Patch.com

Obituaries in the Sunday and Monday Courier, June 28-29 – Waterloo Cedar Falls Courier

DENVER Irene M. Hillson, 97, of Denver, formerly of Waterloo, died Thursday, June 25, at home.

She was born Nov. 15, 1922, in Iowa, daughter of Albert K. and Hilda A. Klooster Johnson. She married Robert G. Bob Todd Hillson on June 1, 1946, in Blue Earth, Minn.; he died Feb. 21, 2009.

She worked as a family assistant for many families at nursing homes and private homes.

Survivors: a son, Daris Hillson of Waterloo; two daughters, Adri (Bob) Lang of Denver, and Betty Otting of Waterloo; four grandchildren, James (Rosie) Hillson, Gregory Jensen, Kendra (Quinn) Taplin, and Kayla (Bryan) Sinclair; a stepgrandson, Ray Soto; two foster grandchildren, Jennie Love and Mickey Henderson; nine great-grandchildren, Monica Rynearson, Ivy Mae Hillson, Payton Hillson, Cora Jensen, Sawyer Jensen, Alaina Taplin, Nora Taplin, Karah Sinclair, and Brock Sinclair; three stepgreat-grandchildren, Olivia, Gabbie and Sophia Soto; and a sister, Lois Patten of Grinnell.

Preceded in death by: her parents; her husband; a sister, Margaret Wirtjes; and a brother, Raymond Johnson.

Services: 1 p.m. Friday, July 3, at Kearns Funeral Service Kimball Chapel with burial in the Garden of Memories Cemetery, both in Waterloo. Visitation is 5 to 7 p.m. Thursday, and also one hour before the service at the funeral home. The family asks that masks be worn. The service will be recorded and posted to the funeral home website.

Memorials: to the family.

Irene enjoyed visiting with family and friends, caregiving, reading and both flower and vegetable gardening.

Kearns Funeral Service Kimball Chapel is in charge of arrangements (319) 233-3146. Online condolences may be left at http://www.kearnsfuneralservice.com.

As a young woman, Irene felt the conviction to follow the teachings of Jesus and became part of a worldwide fellowship of believers. She remained true to that choice the rest of her life.

See the article here:
Obituaries in the Sunday and Monday Courier, June 28-29 - Waterloo Cedar Falls Courier